Bristol-Myers Squibb Co

BMY

Equity

ISIN null / Valor 914188

New York Stock Exchange, Inc (2026-02-19)

USD 60.30+0.95%

Bristol-Myers Squibb Co
UMushroom community rating:

4.00 2 votes No rating yet

NegativeNeutralPositive

About company

Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines, with a commercial focus on oncology, hematology, immunology and cardiovascular disease. Its marketed portfolio includes immuno‑oncology therapies such as nivolumab (Opdivo), the widely used anticoagulant apixaban (Eliquis, co‑developed with Pfizer) and a range of treatments for blood cancers and autoimmune conditions, while its pipeline covers targeted small molecules, biologics and emerging modalities including cell therapies. The company generates revenue from global product sales, licensing and collaboration agreements and supports those commercial activities with substantial R&D and clinical development operations; its 2019 acquisition of Celgene significantly expanded its hematology and oncology franchises. Headquartered in New York, Bristol‑Myers Squibb operates worldwide as a publicly traded pharmaceutical firm.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

9.68%1Y

-15.2%3Y

-0.50%5Y

Performance

29.7%1Y

26.3%3Y

23.7%5Y

Volatility